基线FDG-PET/CT可检测滤泡性淋巴瘤骨髓受累并提供相关预后信息
该研究回顾2002至2016年261例初治滤泡性淋巴瘤患者的PET与骨髓活检记录,PET阳性诊断骨髓受累78例(29.9%),骨髓活检阳性81例(31.0%),任一阳性113例(43.3%);PET使24例升期为IV期。多因素分析中PET阳性是PFS唯一独立预测因素,高FLIPI评分和PET阳性预测OS。
要点
- PET与骨髓活检联合识别骨髓受累比任一单项更准确,但骨髓活检很少增加关键信息。
- PET阳性使24例升期为IV期,其中10例由I或II期升至IV期。
- 多因素分析中PET阳性是PFS唯一独立预测因素,高FLIPI评分和PET阳性预测OS。
核心结论
- PET与骨髓活检联合识别骨髓受累比骨髓活检或PET单独更准确,但骨髓活检很少增加关键信息。
- 对开始治疗的滤泡性淋巴瘤患者,PET识别的骨髓受累可预测PFS和OS。
研究设计与样本
- 回顾性分析2002至2016年261例初治时同时接受PET和骨髓活检的滤泡性淋巴瘤患者记录。
- 骨髓受累由骨髓活检阳性结果和/或盲法阅片PET上无对应CT异常的单灶或多灶骨髓FDG摄取(PET阳性)判定。
主要发现
- 261例中,PET阳性诊断骨髓受累78例(29.9%),骨髓活检阳性81例(31.0%),任一阳性113例(43.3%)。
- PET阳性使24例升期为IV期,其中10例由I或II期升至IV期。
- 中位随访6.0年(范围0-16.6年)。
- 单因素分析中,高FLIPI评分、PET阳性和骨髓活检阳性与较短PFS相关(均P≤.03),高FLIPI、PET阳性及PET阳性联合骨髓活检阳性与较短OS相关(均P≤.01)。
- 多因素分析中,PET阳性是PFS唯一独立预测因素,高FLIPI评分和PET阳性预测OS(P≤.03)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In follicular lymphoma (FL), detection of bone marrow (BM) involvement (BMI) by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) improves the accuracy of staging vs BM biopsy (BMB) alone. Our objective was to determine the diagnostic utility of PET for BMI FL and the prognostic value of BMI by PET (positive PET result [PET+]). Records of patients (2002-2016) with PET and BMB at the time of initial treatment were reviewed. BMI was identified by positive BMB result (BMB+) and/or unifocal or multifocal BM FDG uptake on blindly reviewed PET scans with no corresponding CT abnormality (PET+). Among 261 patients, BMI was diagnosed in 78 patients (29.9%) by PET+, in 81 patients (31.0%) by BMB+, and in 113 patients (43.3%) by either PET+ or BMB+. PET+ upstaged 24 patients to stage IV, including 10 from stages I or II to stage IV. Median duration of follow-up was 6.0 years (range, 0-16.6 years). In univariate analysis, a high Follicular Lymphoma International Prognosis Index (FLIPI) score, PET+, and BMB+ correlated with shorter progression-free survival (PFS; all P ≤ .03), and high FLIPI, PET+, and combined PET+ and BMB+ with shorter overall survival (OS; all P ≤ .01). In multivariate analysis, PET+ was the only independent predictor of PFS, whereas high FLIPI score and PET+ predicted OS (P ≤ .03). Combined PET and BMB identify BMI more accurately than either BMB or PET alone, but BMB rarely adds critical information. For patients initiating treatment of FL, identification of BMI by PET is predictive of PFS and OS.
引用
- Nakajima R, Moskowitz AJ, Michaud L, et al. Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Adv. 2020. PMID: 32343798. doi:10.1182/bloodadvances.2020001579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。